National Institute of Neurological Disorders and Stroke, Muscular Dystrophy Coordinating Committee Call for Committee Membership Nominations, 57379-57380 [2015-24117]
Download as PDF
<![CDATA[
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 184 / Wednesday, September 23, 2015 / Notices
Review Group; Macromolecular Structure
and Function D Study Section.
Date: October 15–16, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications and/or proposals.
Place: Kinzie Hotel, 20 West Kinzie Street,
Chicago, IL 60654.
Contact Person: James W Mack, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4154,
MSC 7806, Bethesda, MD 20892, (301) 435–
2037, mackj2@csr.nih.gov.
Name of Committee: Genes, Genomes, and
Genetics Integrated Review Group; Genetic
Variation and Evolution Study Section.
Date: October 23, 2015.
Time: 8:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Ronald Adkins, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2206,
MSC 7890, Bethesda, MD 20892, 301–435–
4511, ronald.adkins@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
NIH–PEPFAR Collaboration on
Implementation Science for HIV.
Date: October 26–27, 2015.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Shalanda A. Bynum,
Ph.D., MPH, Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive Room 3206,
Bethesda, MD 20892, 301–435–1165,
bynumsa@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Psychosocial and Developmental
Risk and Disease Prevention.
Date: October 27, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Weijia Ni, Ph.D., Chief/
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3100,
MSC 7808, Bethesda, MD 20892, (301) 594–
3292, niw@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 18, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–24202 Filed 9–22–15; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
18:00 Sep 22, 2015
Jkt 235001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke, Muscular
Dystrophy Coordinating Committee
Call for Committee Membership
Nominations
The Office of the Secretary of
the Department of Health and Human
Services (HHS) is seeking nominations
for an individual to serve as a nonfederal public member on the Muscular
Dystrophy Coordinating Committee.
DATES: Nominations are due by 5 p.m.,
October 26, 2015.
ADDRESSES: Nominations must be sent
to Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
FOR FURTHER INFORMATION CONTACT: Glen
Nuckolls, Ph.D., by email to nuckollg@
ninds.nih.gov.
SUPPLEMENTARY INFORMATION: The
Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory
committee established in accordance
with the Muscular Dystrophy
Community Assistance, Research, and
Education Amendments of 2001 (MD–
CARE Act; Pub. L. 107–84). The MD–
CARE Act was reauthorized in 2008 by
Public Law 110–361, and again in 2014
by Public Law 113–166. The MD–CARE
Act specifies that the committee
membership be composed of 2⁄3
governmental agency representatives
and 1⁄3 public members. We are seeking
nominations for a non-federal, public
member at this time, due to turnover of
committee membership. Nominations
will be accepted between September 25,
2015 and October 26, 2015.
Who is Eligible: Nominations for a
new non-federal public member
interested in providing the public and/
or patient perspective are encouraged.
Self-nominations and nominations of
other individuals are both permitted.
Only one nomination per individual is
required. Multiple nominations for the
same individual will not increase
likelihood of selection. Non-federal,
public members may be selected from
the pool of submitted nominations or
other sources as needed to meet
statutory requirements and to form a
balanced committee that represents the
diversity within the muscular dystrophy
communities. Those eligible for
nomination include leaders or
representatives of major muscular
dystrophy research, advocacy, and
service organizations, parents or
guardians of individuals with muscular
dystrophy, individuals with muscular
dystrophy, educators, researchers, and
SUMMARY:
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
57379
other individuals with professional or
personal experience with muscular
dystrophy. In accordance with White
House Office of Management and
Budget guidelines (FR Doc. 2014–
19140), federally-registered lobbyists are
not eligible.
Committee Composition: The
Department strives to ensure that the
membership of HHS Federal advisory
committees is fairly balanced in terms of
points of view represented and the
committee’s function. Every effort is
made to ensure that the views of all
genders, all ethnic and racial groups,
and people with disabilities are
represented on HHS Federal advisory
committees and, therefore, the
Department encourages nominations of
qualified candidates from these groups.
The Department also encourages
geographic diversity in the composition
of the Committee. Appointment to this
Committee shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
disability, and cultural, religious, or
socioeconomic status. Requests for
reasonable accommodation to enable
participation on the Committee should
be indicated in the nomination
submission.
Member Terms: Non-Federal public
members of the Committee serve for a
term of 3 years, and may serve for an
unlimited number of terms if
reappointed. Members may serve after
the expiration of their terms, until their
successors have taken office.
Meetings and Travel: As specified by
Public Law 113–166, the MDCC ‘‘shall
meet no fewer than two times per
calendar year.’’ Travel expenses are
provided for non-federal public
Committee members to facilitate
attendance at in-person meetings.
Members are expected to make every
effort to attend all full committee
meetings, twice per year, either in
person or via remote access.
Participation in relevant subcommittee,
working and planning group meetings,
and workshops, is also encouraged.
Submission Instructions and
Deadline: Nominations are due by 5
p.m. EST on October 26, 2015, and
should be sent to Glen Nuckolls, Ph.D.,
by email to nuckollg@ninds.nih.gov.
Nominations must include contact
information for the nominee, a current
curriculum vitae or resume of the
nominee and a paragraph describing the
qualifications of the person to represent
some portion(s) of the muscular
dystrophy research, advocacy and/or
patient care communities.
More information about the MDCC is
available at https://www.ninds.nih.gov/
about_ninds/groups/mdcc/.
E:\FR\FM\23SEN1.SGM
23SEN1
57380
Federal Register / Vol. 80, No. 184 / Wednesday, September 23, 2015 / Notices
Dated: September 16, 2015.
Walter J. Koroshetz,
Director, National Institute of Neurological
Disorders and Stroke, National Institutes of
Health.
minutes, is highly efficient, and has low
background.
Potential Commercial Applications
• A rapid assay for point-of-care
diagnosis of infectious and autoimmune
diseases.
• Applications to different assay
platforms, such as a portable,
commercially available hand-held
luminometer or an automated, highthroughput device.
[FR Doc. 2015–24117 Filed 9–22–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Competitive Advantages
• Highly efficient, rapid, and easy to
perform.
• Low background signals.
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Development Stage
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by writing to the
indicated licensing contact at the Office
of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follow.
SUMMARY:
mstockstill on DSK4VPTVN1PROD with NOTICES
A Novel Rapid Point-of-Care Diagnostic
Method for Infectious and Autoimmune
Diseases
Description of Technology: Rapid
point-of-care, antibody-based testing is
not available for the diagnosis of
autoimmune and most infectious
diseases. For detecting autoantibodies
associated with most autoimmune
conditions, fluid-phase
immunoprecipitation assays are
required. However, these assays usually
involve radioactivity and are not
feasible for point-of-care applications.
The subject invention describes
methods of using neodymium magnet
for diagnosis of infectious and
autoimmune diseases including lupus,
¨
Sjogren’s syndrome, type I diabetes, HIV
and Lyme disease. The assay takes 3.5
VerDate Sep<11>2014
18:00 Sep 22, 2015
Jkt 235001
• Early-stage
• In vitro data available
• Prototype.
Inventor: Peter D. Burbelo (NIDCR)
Publications
1. Burbelo PD, et al. Luciferase
immunoprecipitation systems for measuring
antibodies in autoimmune and infectious
diseases. Transl Res. 2015 Feb; 165(2):325–
335. [PMID 25241936]
2. Burbelo PD, et al. New autoantibody
detection technologies yield novel insights
into autoimmune disease. Curr Opin
Rheumatol. 2014 Nov; 26(6):717–723. [PMID
25203116]
3. Burbelo PD, et al. Searching for
biomarkers: humoral response profiling with
luciferase immunoprecipitation systems.
Expert Rev Proteomics. 2011 Jun; 8(3):309–
316. [PMID 21679112]
4. Burbelo PD, et al. Antibody profiling by
luciferase immunoprecipitation systems
(LIPS). J Vis Exp. 2009 Oct 7; (32). [PMID
19812534]
Intellectual Property: HHS Reference
No. E–190–2015/0—US Provisional
Application No. 62/212,973 filed 01 Oct
2015.
Related Technologies
• E–036–2010 family: PCT/US2011/
027888, US 8,926,989, issued. US 14/
562,068 and EP 11730770.1, pending.
• E–281–2010: US 13/882,850,
allowed.
• E–063–2009: US 8,951,723, issued.
Licensing Contact: Sally Hu, Ph.D.,
M.B.A.; 301–435–5606; hus@
mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Dental and
Craniofacial Research is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate or
commercialize using neodymium
magnet for rapid diagnosis. For
collaboration opportunities, please
contact David Bradley, Ph.D. at
bradleyda@nidcr.nih.gov.
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
A Mobile Health Platform
Description of Technology: The NIH
inventors have developed a mobile
health technology to monitor and
predict a user’s psychological status and
to deliver an automated intervention
when needed. The technology uses
smartphones to monitor the user’s
location and ask questions about
psychological status throughout the day.
Continuously collected ambulatory
psychological data are fused with data
on location and responses to questions.
The mobile data are combined with
geospatial risk maps to quantify
exposure to risk and predict a future
psychological state. The future
predictions are used to warn the user
when he or she is at especially high risk
of experiencing a negative event that
might lead to an unwanted outcome
(e.g., lapse to drug use in a recovering
addict).
An internally developed mobile app
is now being deployed to deliver an
intervention in the context of drug
addiction. The inventors are also
seeking to test the technology for other
health applications.
Potential Commercial Applications
• Real time behavior monitoring
• Therapeutic delivery of an
intervention via a mobile device
Competitive Advantages
• Mobile device
• Real time
• Exposure to risk
Development Stage: Prototype
Inventors: Kenzie L. Preston, David H.
Epstein, Matthew Tyburski, Massoud
Vahabzadeh (all of NIDA)
Publications
1. Epstein DH, et al. Real-time tracking of
neighborhood surroundings and mood in
urban drug misusers: Application of a new
method to study behavior in its geographical
context. Drug Alcohol Depend. 2014 Jan
1;134:22–9. [PMID 24332365]
2. Kennedy AP, et al. Continuous in-thefield measurement of heart rate: Correlates of
drug use, craving, stress and mood in
polydrug users. Drug Alcohol Depend. 2015
June 1;151:159–66. [PMID 25920802]
Intellectual Property: HHS Reference
No. E–049–2015/0—US Provisional
Application No. 62/186, 983 filed 30
June 2015
Licensing Contact: Betty B. Tong,
Ph.D.; 301–594–6565; tongb@
mail.nih.gov
Collaborative Research Opportunity:
The National Institute on Drug Abuse is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize
E:\FR\FM\23SEN1.SGM
23SEN1
]]>Agencies
[Federal Register Volume 80, Number 184 (Wednesday, September 23, 2015)]
[Notices]
[Pages 57379-57380]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24117]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke, Muscular
Dystrophy Coordinating Committee Call for Committee Membership
Nominations
SUMMARY: The Office of the Secretary of the Department of Health and
Human Services (HHS) is seeking nominations for an individual to serve
as a non-federal public member on the Muscular Dystrophy Coordinating
Committee.
DATES: Nominations are due by 5 p.m., October 26, 2015.
ADDRESSES: Nominations must be sent to Glen Nuckolls, Ph.D., by email
to nuckollg@ninds.nih.gov.
FOR FURTHER INFORMATION CONTACT: Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
SUPPLEMENTARY INFORMATION: The Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory committee established in
accordance with the Muscular Dystrophy Community Assistance, Research,
and Education Amendments of 2001 (MD-CARE Act; Pub. L. 107-84). The MD-
CARE Act was reauthorized in 2008 by Public Law 110-361, and again in
2014 by Public Law 113-166. The MD-CARE Act specifies that the
committee membership be composed of \2/3\ governmental agency
representatives and \1/3\ public members. We are seeking nominations
for a non-federal, public member at this time, due to turnover of
committee membership. Nominations will be accepted between September
25, 2015 and October 26, 2015.
Who is Eligible: Nominations for a new non-federal public member
interested in providing the public and/or patient perspective are
encouraged. Self-nominations and nominations of other individuals are
both permitted. Only one nomination per individual is required.
Multiple nominations for the same individual will not increase
likelihood of selection. Non-federal, public members may be selected
from the pool of submitted nominations or other sources as needed to
meet statutory requirements and to form a balanced committee that
represents the diversity within the muscular dystrophy communities.
Those eligible for nomination include leaders or representatives of
major muscular dystrophy research, advocacy, and service organizations,
parents or guardians of individuals with muscular dystrophy,
individuals with muscular dystrophy, educators, researchers, and other
individuals with professional or personal experience with muscular
dystrophy. In accordance with White House Office of Management and
Budget guidelines (FR Doc. 2014-19140), federally-registered lobbyists
are not eligible.
Committee Composition: The Department strives to ensure that the
membership of HHS Federal advisory committees is fairly balanced in
terms of points of view represented and the committee's function. Every
effort is made to ensure that the views of all genders, all ethnic and
racial groups, and people with disabilities are represented on HHS
Federal advisory committees and, therefore, the Department encourages
nominations of qualified candidates from these groups. The Department
also encourages geographic diversity in the composition of the
Committee. Appointment to this Committee shall be made without
discrimination on the basis of age, race, ethnicity, gender, sexual
orientation, disability, and cultural, religious, or socioeconomic
status. Requests for reasonable accommodation to enable participation
on the Committee should be indicated in the nomination submission.
Member Terms: Non-Federal public members of the Committee serve for
a term of 3 years, and may serve for an unlimited number of terms if
reappointed. Members may serve after the expiration of their terms,
until their successors have taken office.
Meetings and Travel: As specified by Public Law 113-166, the MDCC
``shall meet no fewer than two times per calendar year.'' Travel
expenses are provided for non-federal public Committee members to
facilitate attendance at in-person meetings. Members are expected to
make every effort to attend all full committee meetings, twice per
year, either in person or via remote access. Participation in relevant
subcommittee, working and planning group meetings, and workshops, is
also encouraged.
Submission Instructions and Deadline: Nominations are due by 5 p.m.
EST on October 26, 2015, and should be sent to Glen Nuckolls, Ph.D., by
email to nuckollg@ninds.nih.gov.
Nominations must include contact information for the nominee, a
current curriculum vitae or resume of the nominee and a paragraph
describing the qualifications of the person to represent some
portion(s) of the muscular dystrophy research, advocacy and/or patient
care communities.
More information about the MDCC is available at https://www.ninds.nih.gov/about_ninds/groups/mdcc/.
[[Page 57380]]
Dated: September 16, 2015.
Walter J. Koroshetz,
Director, National Institute of Neurological Disorders and Stroke,
National Institutes of Health.
[FR Doc. 2015-24117 Filed 9-22-15; 8:45 am]
BILLING CODE 4140-01-P
